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PathogenesisThe vaccinia virus A43R open reading frame encodes a 168-amino acid protein with a predicted N-terminal
signal sequence and a C-terminal transmembrane domain. Although A43R is conserved in all sequenced
members of the orthopoxvirus genus, no non-orthopoxvirus homolog or functional motif was recognized.
Biochemical and confocal microscopic studies indicated that A43 is expressed at late times following viral
DNA synthesis and is a type-1 membrane protein with two N-linked oligosaccharide chains. A43 was present
in Golgi and plasma membranes but only a trace amount was detected in sucrose gradient puriﬁed mature
virions and none in CsCl gradient puriﬁed enveloped virions. Prevention of A43R expression had no effect on
plaque size or virus replication in cell culture and little effect on virulence after mouse intranasal infection.
Although the A43 mutant produced signiﬁcantly smaller lesions in skin of mice than the control, the amounts
of virus recovered from the lesions were similar.
Published by Elsevier Inc.Introduction
The Poxviridae, a group of large, complex DNA viruses that replicate
exclusively in the cytoplasm, are divided into the Chordopoxvirinae and
Entomopoxvirinae subfamilies (Moss, 2007). The chordopoxviruses
consist of eight genera of which the orthopoxviruses are best known
because of twomembers: variola virus, the causative agent of smallpox,
and vaccinia virus (VACV), used to eradicate smallpox by prophylactic
immunization. VACV, the prototype poxvirus, encodes ∼200 genes
nearly half of which are present in all chordopoxviruses (Upton et al.,
2003). The evolutionarily conserved genes tend to be centrally located
within the genome and are mostly involved in essential replication
functions, while the genus- and species-speciﬁc genes are nearer the
ends of the genome and typically involved in host interactions. Proteins
that are dispensable for poxvirus replication in cell culture can have a
wide variety of roles that directly or indirectly affect virulence by
enabling virus spread or resisting immune defenses (Fallon and Alcami,
2006; McFadden, 2005). Studies of such genes can contribute to our
understanding of cell biology and immunology and are important for
development of vaccines and antivirals.
Since not all VACV genes have been characterized, it seems likely
that additional proteins involved in host interactions will be discov-
ered. The A43R open reading frame (ORF) is a candidate as it is
embedded within the variable region of the genome. For example, theInc.A41L ORF encodes a chemokine binding protein (Bahar et al., 2008) and
the protein encoded by A46R inhibits TLR signaling (Stack et al., 2005).
In this study we provided the initial characterization of A43, the
product of the A43R ORF, which was expressed after viral DNA
replication as a glycosylated protein that associated with Golgi and
plasma membranes but was not appreciably incorporated into virus
particles. The gene was found to be dispensable for VACV replication in
cell culture but caused smaller than normal intradermal lesions inmice.
Results
A43R is conserved among orthopoxviruses
The A43R ORF (VACVWR168) is predicted to encode a 194-amino
acid proteinwithN- andC-terminal hydrophobic domains. The SignalP
program (Bendtsen et al., 2004) predicted that the N-terminal hydro-
phobic region is a signal sequence with cleavage occurring between
S22 and S23 (Fig. 1). A43R is highly conserved within all orthopox-
viruses; the sequence identity is N94% except for ectromelia virus
which has a 78% identity (Fig. 1). However, there are no recognized
homologs in any other poxvirus genus, nor are there non-poxvirus
homologs or functional motifs to help predict the function of A43.
A43 is a glycosylated protein expressed at the late stage of VACV
replication
A recombinant virus, in which a V5 epitope tag was added to the
C-terminus of A43, was constructed to assist in protein character-
Fig. 1.Multiple sequence alignment of A43 orthologs. Jalview (Waterhouse et al., 2009) was used to construct a multiple sequence alignment of A43 orthologs from orthopoxvirus
species. The ORFs are indicated after the species and strain names. Abbreviations: VACV-WR, VACV strainWR; CMLV-M96, camelpox virus strain M96; CPXV-BR, cowpox virus strain
Brighton; ECTV-Mos, ectromelia virus strain Moscow; MPXV-WR267, monkeypox virus Walter Reed 267; RPXV, rabbitpox virus strain Utrecht; VACV-MVA, VACV strain Modiﬁed
VACV Ankara; VARV-AFG70, variola virus strain Afghanistan 1970. The asterisks indicate the Asn-X-Ser/Thr potential glycosylation sites. The predicted transmembrane domain is
underlined. Note that the numbering includes spaces for alignment so does not correspond precisely to the VACV sequence.
Fig. 2. A43 synthesis and glycosylation. (A) Western blot analysis of A43 expression
kinetics. BS-C-1 cells were infected at amultiplicity of 10 PFU per cell with vA43V5. At 0,
2, 4, 6, 8, 12 and 24 h post-infection, whole cell lysates were analyzed by SDS-PAGE and
Western blotting with an antibody to the V5 epitope tag. The blot was stripped and
reprobed with an antibody to the VACV late protein A3. Position and mass in kDa of
marker proteins are shown on the left. (B) vA43V5 infected cell lysates were treated
with (+) or without (−) Endo H or PNGase F and analyzed by SDS-PAGE and Western
blotting with an antibody to the V5 epitope tag.
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was unaltered so as not to perturb expression. The growth kinetics
and plaque phenotype of vA43V5 were similar to that of the parental
virus (not shown). The sequence TAAATG, present at the start of the
A43R ORF, is a characteristic of late promoters (Davison and Moss,
1989). To experimentally determine the time of synthesis of A43V5,
BS-C-1 cells were infected with the recombinant virus and whole cell
lysates were prepared at intervals and analyzed by SDS-polyacryl-
amide gel electrophoresis (PAGE) and Western blotting. A band
visualized by binding of the anti-V5 MAb migrated more slowly than
the predicted 23-kDa mass of A43V5 (Fig. 2A). The band was detected
at 0 time, indicating its presence in the unpuriﬁed virus inoculum, but
did not increase signiﬁcantly until 6 h and then continued to increase
up to 24 h. This pattern was similar to that of the well-characterized
late A3 protein (Fig. 2A). Neither A43 nor A3 was synthesized in the
presence of the DNA replication inhibitor AraC (data not shown),
which is indicative of VACV proteins expressed at the late stage of
infection.
Inspection of the predicted amino acid sequence of A43 revealed
three potential N-glycosylation sites that could account for the
relatively slow electrophoretic migration of A43. To determine the
state of glycosylation of A43, a whole cell lysate from vA43V5
infected cells was divided into portions that were untreated or
treated with peptide: N-glycosidase F (PNGase F) or endoglycosidase
H (Endo H). PNGase F is capable of removing all types of N-linked
oligosaccharides, whereas Endo H removes only high mannose and
some hybrid types of oligosaccharides. Both glycosidases caused an
increase in the mobility of A43V5 as determined by SDS-PAGE and
Western blotting (Fig. 2B), consistent with N-glycosylation of the
protein.
A43 has two N-linked glycosylation sites
To determine the number and sites of glycosylation, plasmids
(pA43HAN65Q, pA43HAN93Q, pA43HAN114Q) were constructed,
each with a mutation in one of the three predicted N-linked glyco-
sylation sites of A43 (Fig. 1). Each plasmid expressed A43 under its
natural promoter and with a C-terminal HA epitope tag. An addi-tional plasmid (pA43HA) was constructed with none of the glyco-
sylation sites mutated as a control. To analyze the expression of
the mutated forms of A43, BS-C-1 cells were infected with vΔA43GFP
(a recombinant virus with a deletion of A43 to be described below)
and then transfected with the plasmids. The cells were lysed and the
extracts were analyzed by SDS-PAGE and Western blotting using
antibody to the HA tag. If each of the N-X-S/T consensus sequences
were glycosylated, then we would expect to see an increase in the
Fig. 4. Analysis of A43 in EV, MV and whole cell extract. BS-C-1 cells were infected with
vA43V5; MVs were puriﬁed from cell lysates and EVs from the medium. Antibodies to
the V5 epitope on A43V5, the EV protein B5, and the MV protein A3 were used to probe
Western blots of the whole cell extract (WCE), puriﬁed EVs and puriﬁed MVs as
indicated.
162 C.L. Sood, B. Moss / Virology 396 (2010) 160–168mobility of each protein compared to A43HA. However, we found
that only two of the three mutated proteins, A43HAN65Q and
A43HAN114Q, migrated faster than the unmutated A43HA (Fig. 3A).
To conﬁrm and extend this ﬁnding, we partially digested the
infected/transfected cell lysate with PNGase F and examined the
resulting protein migration patterns. Partial digestion of A43HA and
A43HAN93Q resulted in two new bands that migrated more rapidly
than the uncleaved protein (Fig. 3B), consistent with two N-linked
oligosaccharides. Furthermore, the slower of the two new bands
migrated in the same position as the undigested A43HAN65Q and
A43HAN114Q, indicating removal of a single oligosaccharide.
Digestion of A43HAN65Q and A43HAN114Q produced a band that
migrated with the faster of the bands produced by digestion of
A43HA and A43HAN93Q (Fig. 3B). Taken together, these results
proved that A43 was N-glycosylated at positions N65 and N114. The
absence of glycosylation at N93 is consistent with the presence of the
neighboring proline (Bause, 1983).
A43 associates with cellular membranes
The recombinant virus vA43V5 was used to determine whether
A43 is a component of theMV or EVmembrane. After RK-13 cells were
infected with vA43V5, EVs were puriﬁed from the medium on a CsCl
density gradient and theMVswere puriﬁed from the cell lysate by two
sucrose cushions followed by a sucrose density gradient. Puriﬁed
virions as well as whole cell extracts were analyzed by SDS-PAGE and
immunoblotting. A43was readily detected in whole cell lysate but not
in EVs and just barely in MVs (Fig. 4). Both membranes were stripped
and reprobed with either the EV protein B5 or the MV core protein A3.
A3 and B5 were detected at similar levels in the cell extract and
puriﬁed MVs and EVs, respectively (Fig. 4). Comparison of the relative
amounts of A43, A3 and B5 in extracts and puriﬁed virions suggested
that the slight amount of A43 in MVs was adventitious and likely due
to some membrane contamination that is invariably present in
sucrose gradient puriﬁed virions (B.M., unpublished). This interpre-
tation is supported by the absence of A43 in CsCl gradient puriﬁed EVs.
In addition, it would be unprecedented for an MV membrane protein
to be N-glycosylated.
Further experiments were performed to determine whether A43
localized in virus factories or cellular membranes. After infection with
vA43V5, the cells were ﬁxed, permeabilized with Triton X-100, and
stained with an anti-V5 antibody followed by a ﬂuorescently labeled
secondary antibody. 4′-6′-Diamidino-2-phenylindole (DAPI) wasFig. 3. A43 has two N-linked oligosaccharides. (A) Expression of wild-type andmutated
A43HA. BS-C-1 cells were infected with vΔA43GFP and transfected with one of four
plasmids expressing wild-type A43HA or A43HA with mutations N65Q, N93Q, or
N114Q. Cell extracts were analyzed by SDS-PAGE and Western blotting with anti-HA
antibody. (B) Partial (+) or mock (−) PNGase digestion of cell extracts at 24-h post-
infection with vΔA43GFP and transfection with pA43HA, pN65Q, pN93Q, or pN114Q.
The digests were analyzed by Western blotting with antibody to the HA epitope tag.used to detect DNA in nuclei and cytoplasmic factories, the sites of
viral DNA replication and virion assembly. The A43V5 protein
predominantly colocalized with β-cop, a speciﬁc Golgi complex
protein (Fig. 5A). There was negligible background staining of cells
infected with VACV WR, which lacks the V5 epitope tag (Fig. 5A). The
lack of factory staining was consistent with the absence of A43 in
virions. Co-localization with a Golgi membrane marker also occurred
when uninfected cells were transfected with a plasmid expressing
A43V5 under the cytomegalovirus promoter (data not shown),
indicating that the protein has an intrinsic ability to enter the
secretory pathway.
A43 is a type-1 transmembrane protein
Triton X-100 permeabilizes all cell membranes, allowing antibody
binding to both cytoplasmic and luminal domains of proteins. In
contrast, digitonin selectively permeabilizes the plasma membrane,
making it useful for determining protein topology. After infection
with vA43V5, the epitope tag was detected in digitonin-treated cells
but not in untreated cells (Fig. 5B). Consequently, A43 must be a
type-1 transmembrane protein since the C-terminus containing the
V5 tag is cytoplasmic. Therefore, the segment from amino acids 26 to
164 must be luminal, consistent with our ﬁnding that A43 is
glycosylated at N65 and N114. As a control, the cells infected with
vA43V5 were also stained with an antibody to the luminal domain of
B5, a viral type-1 membrane protein that is present at the cell surface
and the Golgi complex (Isaacs et al., 1992). As predicted, B5 was
detected at the cell surface of intact and digitonin-permeabilized
cells (Fig 5B).
In addition to detecting A43V5 associated with the Golgi appa-
ratus, there was some staining of the plasma membrane, which
partially overlapped that of B5 in digitonin-treated cells (Fig. 5B). To
conﬁrm the trafﬁcking of A43 through the secretory pathway, we
deleted the putative transmembrane domain of A43 in the plasmid
pA43HA to form pA43HAΔTM. BS-C-1 cells were then infected with
vΔA43GFP and transfected with the pA43HA or pA43HAΔTM. After
24 h, the medium was collected and concentrated. The cells were
also harvested and lysed. After SDS-PAGE and Western blotting,
A43HA was detected only in the cell lysate, whereas A43HAΔTM
was detected in the lysate and as a secreted protein in the medium
(Fig. 6A).
To verify that the intact A43 trafﬁcs to the plasma membrane, cells
infected with vA43V5 in the presence or absence of brefeldin A were
surface labeled with biotin. Brefeldin A was used as a control since it
inhibits the transport of proteins from the ER to the Golgi complex.
We afﬁnity puriﬁed the biotinylated proteins and found that A43V5
was captured exclusively from cells that were not treated with
brefeldin A (Fig. 6B). Based on all of the above data, we concluded that
Fig. 5. Intracellular localization and topology of A43. (A) Intracellular localization. HeLa cells were infected with VACV (WR) or vA43V5 at a multiplicity of 0.5 PFU per cell. At 24 h
after infection, cells were ﬁxed, permeabilized and stained with antibodies to V5 and β-Cop followed by ﬂuorescently labeled secondary antibodies (red and green, respectively).
DNAwas stainedwith DAPI (blue). Confocal microscopy images are shown. Arrows point to cytoplasmic virus factories. (B) Topology. Hela cells infected with vA43V5 were ﬁxed and
left unpermeabilized (top panels) or permeabilizedwith digitonin (bottom panels). Cells were then stained with an antibody to the EV protein B5 (green) as well as with an antibody
to the V5 epitope tag (red) followed by ﬂuorescently labeled secondary antibodies. DAPI or Hoechst was used to stain DNA (blue). Confocal microscopy images are shown. Arrows
point to cytoplasmic virus factories.
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glycosylation occurs and continues to the Golgi complex where it is
concentrated and then to the plasma membrane where the long N-
terminal domain is extracellular.
A43 is dispensable for VACV replication and cell-to-cell spread in
cultured cells
An A43R null mutant was constructed in order to investigate the
function of the protein in the VACV life cycle. A43R was deleted from
VACV by homologous recombination with a plasmid containing theGFP ORF regulated by the VACV P11 promoter ﬂanked by A44R and
A42L sequences. Recombinant virus vΔA43GFP was detected by
ﬂuorescent microscopy and clonally puriﬁed by repeated plaque
isolation, indicating that A43R was non-essential. The deletion of
A43R was conﬁrmed by PCR and sequence analysis. BS-C-1 cells were
infected with the parental VACV or the vΔA43GFP and the virus yields
determined at intervals. The growth curves were virtually superim-
posable (Fig. 7A) and plaques formed by wild-type and vΔA43GFP
viruses were similar in BS-C-1 (Fig. 7B) and several other cell lines,
namely, BHK, CV-1, HeLa, HuTK−, RK-13, A549 cells and primary
human epidermal keratinocytes (data not shown).
Fig. 6. Intracellular trafﬁcking of A43. (A) BS-C-1 cells were infected with vΔA43GFP
followed by transfection with plasmids expressing the full length HA-tagged A43
(pA43HA) or a truncated version missing the transmembrane domain (pA43HAΔTM).
After 24 h, the proteins in the cell lysates (L) or concentrated medium (M) were
analyzed by Western blotting with an antibody to the HA tag. (B) HeLa cells were
infected with vA43V5 and brefeldin A was added to one culture after 4 h. At 18 h post-
infection, the cells were allowed to react with a membrane-impermeable biotin
reagent. The biotinylated proteins were afﬁnity puriﬁed on NeutrAvidin gel beads.
Western blotting with V5 antibody was performed on the input (I), unbound (U) and
bound and eluted (E) proteins.
Fig. 7. Replication of A43R deletion mutant. (A) One-step growth curve. BS-C-1 cells
were infected at a multiplicity of 10 PFU/cell with vΔA43GFP and VACV WR. Virus
yields were determined at the indicated times post-infection by plaque assay. (B)
Formation of vΔA43GFP and VACV WR plaques. BS-C-1 cells were infected with
vΔA43GFP and VACV WR using a methylcellulose overlay. Cells were ﬁxed and stained
with crystal violet at 48 h after infection. (C) Comet formation. BS-C-1 cells were
infected with VACV IHD-J or the A43 deletion mutant in the IHD-J background
IHDΔA43GFP using a liquid overlay. After 48 h, the cells were stained as in (A).
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a second deletion mutant was made in the VACV IHD-J strain
background. IHD-J is known for the release of large numbers of EV
that form comet-shaped plaques in liquid medium (Payne, 1980) due
to a point mutation in the A34R gene (Blasco et al., 1993). As shown in
Fig. 7C, deletion of A43R had no effect on comet formation.
Virulence of A43 null mutants in animal models
Since vΔA43GFP showed no apparent replication defect in cell
culture, we considered that it might have a role in animal infections.
Before initiating such experiments, we made two additional recom-
binant viruses. A control revertant virus vA43Rev was constructed by
replacing the GFP ORF of vΔA43GFP with the wild-type A43R ORF to
be sure that there were no extraneous mutations that might affect
animal studies. The second virus, vA43V5stop, was constructed by
replacing the GFP ORF of vΔA43GFP with the A43RV5 ORF containing
a point mutation at nucleotide 68 that caused an immediate stop
codon. The absence of A43V5 expression was veriﬁed by Western
blotting (not shown). The purpose of the latter mutant was to rule out
any possibility that GFP expression regulated by the P11 promoter has
a subtle effect on the virus ﬁtness.
First, we evaluated the virulence of the mutant virus in an
intranasal (IN) respiratory model (Turner, 1967). At a dose of 104
PFU, the weight loss curves of groups of 10 mice inoculated with
vA43Rev and vA43V5stop were superimposable (Fig. 8A). Except for
one mouse that had been infected with vA43V5Rev, all of the mice
survived (Fig. 8B). At a dose of 105 PFU, 3 of 10 mice receiving
vA43Rev survived and none of the mice receiving vA43V5stop
survived (Figs. 8C and D). At a dose of 106 PFU, none of the mice in
either group survived (not shown). Thus, A43V5 expression had no
major effect on VACV virulence in this model.
Next, we compared the virulence of vA43V5stop and vA43Rev in a
mouse intradermal model (Tscharke and Smith, 1999). Groups of 5BALB/c mice were inoculated intradermally in the ear pinna with 104
PFU of vA43V5stop or vA43Rev. Once lesions appeared, they were
measured daily using digital calipers. The lesions reached a maximal
size on day 8 and gradually decreased from day 12 (Fig. 9A). Mice that
received vA43stop had signiﬁcantly smaller lesions over the entire
course of the infection (p= 0.001, Mann–Whitney test) than themice
that received vA43Rev (Fig. 9A). Examination of hematoxylin and
eosin stained sections of lesions from animals infected with the null
mutant and revertant revealed proliferation of keratinocytes and
Fig. 8. Virulence of A43R null mutant after respiratory infection. Groups (n=10) of 7-week-old mice remained untreated as weight controls (WC) or were inoculated via the IN route
with 104 (A and B) or 105 PFU (C and D) of vA43V5stop or vA43Rev. Mice were weighed daily for 2 weeks following challenge and were euthanized if they lost 30% of their initial
body weight. Percent of original weight was plotted in (A) and (C) and percent survival in (B) and (D).
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that previously described (Tscharke and Smith, 1999). The amounts of
virus present in the lesions peaked at day 5 and gradually decreased,
with no difference between the groups (Fig. 9B). In C57BL/6 mice the
lesions produced by vA43V5stop were also smaller than those
produced by vA43Rev (p=0.005), although the lesions of both
were larger than in BALB/c mice and the difference was less.
Discussion
The major conclusions regarding A43 are that the protein (i) is
conserved in all orthopoxviruses but not other poxvirus genera or
non-poxviruses, (ii) contains no obvious functional motifs, (iii) is a
late protein expressed after viral DNA replication, (iii) is not spe-
ciﬁcally associated with MVs or EVs, (iv) contains N-linked oligosac-
charides at two sites, (iv) concentrates in Golgi membranes and
trafﬁcs to plasma membrane, (v) exhibits a type-1 membrane topo-
logy, (vi) is dispensable for replication in tissue culture cells, (vii) null
mutant retains virulence in mice by IN route, and (viii) null mutant
produces smaller intradermal lesions in mice.
The conservation of A43 homologs in all orthopoxviruses,
including the highly passaged MVA strain, led us to think that the
protein has a replication function. The predicted late promoter and
transmembrane domain further suggested that A43 might be an EV
membrane protein with a role in virus egress. Nevertheless, this was
not the case as A43 was not associated with the EV and neither plaque
size nor comet formation was altered. Indeed, with regard to tissue
culture studies A43R null mutants were indistinguishable in every
respect from the parental WR or IHD-J strain of VACV. In view of these
results, we considered that A43 is likely involved in host interactions
and that the null mutant would be attenuated in animal models. We
were surprised therefore to ﬁnd that the A43 null mutant was asvirulent as the revertant in the mouse IN model. However, the null
mutant made smaller lesions than the revertant in mouse ear pinnae
when injected intradermally. The increased thickness of the lesion is
due to proliferation of epidermal cells and leukocyte inﬁltration
(Tscharke and Smith, 1999). We conﬁrmed previous data that
replication of VACV in the ear pinna reaches a peak on days 4–5 and
the titer starts declining before the lesion reaches a maximal size
several days later (Tscharke and Smith, 1999). Despite the difference
in lesion size, the titers of mutant and revertant viruses were similar
to each other at all time points. The similar titers may be related to the
observation that the same amounts of virus are produced when the
inocula vary over a 100-fold range (Tscharke and Smith, 1999).
Unreduced titers and smaller lesions were also found with the B7R
deletion mutant (Price et al., 2000).
Taken together the above characteristics differentiate A43R from
other replication dispensable genes. The majority of such genes have
early rather than late promoters, which would seem to be generally
advantageous if the product interacts with the host. The ﬁve
previously characterized replication dispensable late genes consist
of A14.5L (Betakova et al., 2000), A39R (Comeau et al., 1998; Gardner
et al., 2001), A55R (Beard et al., 2006), B7R (Price et al., 2000), I5L
(Sood et al., 2008) and F3L (Froggatt et al., 2007). Except for A55R,
absence of the gene resulted in attenuation in either the IN (A14.5,
I5L) or intradermal (A39, B7R, F3L) mouse model. Loss of A55 actually
increased skin lesion size. As pointed out above, the B7R and A43R null
mutants exhibited decreased skin lesion size. The retention of
virulence in the IN mode by the B7R null mutant was also similar to
that of the A43R mutant (Price et al., 2000). There are, however,
substantial differences between B7 and A43; B7 localizes in the lumen
of the ER whereas A43 is a type-1 membrane protein in Golgi and
plasma membranes. It had been suggested that B7 might sequester a
cell protein in the ER, though that has not yet been demonstrated.
Fig. 9. Intradermal replication and lesion formation by A43R null mutant. (A) Groups of
ﬁve BALB/c mice were infected intradermally in the ear pinnae with 104 PFU of
vA43Rev or vA43V5Stop. Lesion sizes were determined daily with digital calipers to the
nearest 0.5 mm. Standard errors of the mean are shown. (B) Mice were sacriﬁced and
virus titers were determined from three individual ears by plaque assay on BS-C-1 cells.
Standard errors are shown.
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apparatus, its presence on the plasma membrane suggests that it
interacts with a cell protein, perhaps a cytokine. Efforts to ﬁnd an A43
interacting protein would seem worthwhile for future studies.
Materials and methods
Cells and viruses
BS-C-1 cells were propagated in minimum essential medium with
Earle's salts supplemented with 10% fetal bovine serum, 100 U/ml of
penicillin, and 100 μg/ml of streptomycin. HeLa cells were propagated
in Dulbecco's modiﬁed Eagle's medium supplemented with 10% fetal
bovine serum and antibiotics as described above. The VACVWR strain
and recombinant viruses were prepared as previously described (Earl
et al., 1998).
Plasmid and recombinant VACV construction
To construct the recombinant vΔA43GFP, the ﬂanking regions of
the A43R ORF were ampliﬁed from VACV strain WR genomic DNA
template using oligonucleotides ct49 (5′-ATG CTA ATG TCA AGT TTA
TTC CAA TAG ATG TCT TAT TAA AAA ACA TAT AT-3′), ct51 (5′-CAT
AGA AAA AAA CAA AAT GAA ATT CTT AAA ATT GAC ACT ACA TAT GAA
TAT-3′), ct52 (5′-GCA TGG ACG AGC TGT ACA AGT AAT TAT GCT ATG
CTA TTA GAA ATG-3′), and ct54 (5′-CTA TTT AGA AAA CCA TCA CTA
CTC AAC AAC TAT ACG TTG AAG ATA TCC AAC-3′). The ORF for GFP
under the VACV promoter p11 was ampliﬁed using primers ct50(5′-ATA TTC ATA TGT AGT GTC AAT TTT AAG AAT TTC ATT TTG TTT TTT
TCT ATG-3′) and ct53 (5′-CAT TTC TAA TAG CAT AGC ATA ATT ACT
TGT ACA GCT CGT CCA TGC-3′). Primers ct50 and ct51 as well as ct52
and ct53 were designed to complement each other. The above
products were used in a second recombinant PCR to yield a GFP ORF
ﬂanked by regions up- and downstream of A43R. The resulting PCR
product was gel puriﬁed and ligated into pCR-BluntII-Topo (Invitro-
gen, Carlsbad, CA), resulting in pΔA43GFP. The endogenous A43R ORF
was replaced with the GFP reporter gene by homologous recombina-
tion after transfection (Lipofectamine 2000; Invitrogen) of pΔA43GFP
into VACV WR-infected cells. Recombinant viruses expressing GFP
were detected with an inverted ﬂuorescence microscope and isolated
by three rounds of plaque puriﬁcation. The correct site of recombi-
nation was veriﬁed by PCR analysis. A similar procedure was used to
delete the A43R ORF from the IHD-J strain of VACV to form
IHDΔA43GFP.
Recombinant vA43V5 was derived from vΔA43GFP. The primers
ct61 (5′-AAT GCT AAT GTC AAG TTT ATT CCA ATA GAT GTC TTA TTA
AAA ACA TAT AT-3′), ct62 (5′-ACC GAG GAG AGG GTT AGG GAT AGG
CTT ACC AGA GTT CAT TTT TAT TTT TTT-3′), ct63 (5′-TAT CCC TAA CCC
TCT CCT CGG TCT CGA TTC TAC GTA ATT ATG CTA TGC TAT TA-3′), and
ct54 were used to amplify A43R from genomic DNA and incorporate a
C-terminal V5 tag. Non-ﬂuorescent plaques were picked and clonally
puriﬁed by repeated isolations.
The A43 revertant virus (vA43Rev) was derived from vΔA43GFP.
Primers ct61 and ct54were used to generate a PCR product containing
the A43R gene including 500 bp up- and downstream sequence. The
PCR product was gel puriﬁed and ligated into pCR-BluntII-Topo
(pA43Rev). Homologous recombination was used to replace the GFP
gene with the A43R ORF after transfection of pA43Rev into cells
infected with vΔA43GFP. Non-GFP-expressing plaques were picked
and isolated by three rounds of plaque puriﬁcation. The correct site of
recombination was veriﬁed by PCR and sequence analysis. An A43V5−
virus (vA43V5stop) was also derived from vΔA43GFP. A stop codon
was generated in the A43R sequence of pA43V5 by using a
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA)
with PCR oligonucleotides containing the desired mutation. Primers
ct79 (5′-CCG GTA TTG GCA TAC AGC TAA TCG ATT TTT AGA TTT CAT
TCA GAG-3′) and ct80 (5′-CTC TGA ATG AAA TCT AAA AAT CGA TTA
GCT GTA TGC CAA TAC CGG-3′) were used to change nucleotide 68,
resulting in an immediate stop codon. Homologous recombination
was used to replace the GFP marker gene with the A43V5stop
sequence after transfection of pA43V5stop into vΔA43GFP-infected
cells. Again, non-GFP-expressing plaques were picked and isolated by
three rounds of plaque puriﬁcation. The correct site of recombination
was veriﬁed by PCR and sequence analysis.
Primers ct61 (5′-AAT GCT AAT GTC AAG TTT ATT CCA ATA GAT GTC
TTA TTA AAAACA TAT AT-3′), ct88 (5′-TAC CCA TAC GATGTT CCA GAC
TAC GCT TAA TTA TGC TAT GCT ATT AGA AAT-3′), ct89 (5′-TAA TTA
AGC GTA GTC TGG AAC ATC GTA TGG GTA AGA GTT CAT TTT TAT TTT
TTT-3′), and ct54 were used to amplify A43R from genomic DNA and
incorporate a C-terminal HA tag. The PCR product was gel puriﬁed and
ligated into pCR-BluntII-Topo (pA43HA). pN65Q, pN93Q, and pN114Q
were generated in the A43R sequence of pA43HA by using a
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA)
with PCR oligonucleotides containing the desired mutation. Primers
ct101 (5′-CCA TAT AGA TAT AAT TTT ATT CAG CGC ACG TTA ACC GTA
GAT GAA C-3′) and ct102 (5′-GTT CAT CTA CGG TTA ACG TGC GCT
GAA TAA AAT TAT ATC TAT ATG G-3′) were used for pN65Q. Primers
ct103 (5′-CAC AAA TAT GGT TCA CTT CAG CCT AGT TTG ATT GTC TCA
TTA TC-3′) and ct104 (5′-GAT AAT GAG ACA ATC AAA CTA GGC TGA
AGT GAA CCA TAT TTG TG-3′) were used for pN93Q. Primers ct105
(5′-CAA TGC TCA GTA CAGGTA TCG TGT CTC ATT AAA AAT TTG GC-3′)
and ct106 (5′-GCC AAA TTT TTA ATG AGA CAC GAT ACC TGT ACT GAG
CAT TG-3′) were used for pN114Q. pA43HAΔTM was constructed
fromWR genomic DNA using primers ct64 (5′-TAA TTA AAA TAA AAA
167C.L. Sood, B. Moss / Virology 396 (2010) 160–168GTA ATA TTC ATA TGT AGT GTC AAT TTT AAA TGA TGA-3′) and ct90
(5′-TTA AGC GTA GTC TGG AAC ATC GTA TGG GTA ATT ATA CTT GTC
ATT TAT ATC TTT AT-3′) in a PCR reaction to amplify the A43 coding
region under the natural promoter, delete the transmembrane domain
and maintain the HA tag sequence. The PCR product was gel puriﬁed
and ligated into pCR-BluntII-Topo (pA43HAΔTM). All constructed
plasmid sequences and mutations were veriﬁed by sequence analysis.
Glyscosidase treatment of cell lysate
Cells (106) were washed and lysed in 75 μl of 50 mM Tris, pH 7.0,
150 mM NaCl and 1% NP-40 detergent on ice for 20 min. Nuclei were
removed by low-speed centrifugation and SDS and β-mercaptoetha-
nol were added to achieve ﬁnal concentrations of 0.5% and 1%,
respectively, and heated at 95 °C for 10 min. PNGase (2500 U; New
England BioLabs, Ipswich, MA) was added and incubated at 37 °C
overnight or for 1 h to achieve complete or partial digestion,
respectively. Digestion with Endo H (New England BioLabs) was
carried out similarly overnight. Samples were analyzed by SDS-PAGE
and Western blotting.
EV puriﬁcation
RK-13 cells were infected with either VACV or vA43V5. At 48 h
post-infection, the medium was harvested and clariﬁed by low-speed
centrifugation for 20 min. EVs were pelleted by centrifugation at
14,000×g for 1 h at 4 °C. The EVswere gently resuspended and further
puriﬁed by layering over a preformed CsCl gradient as described
previously (Domi et al., 2008) and centrifuged at 32,000 rpm in an
SW41 rotor for 4 h at 20 °C. Fractions collected from the top of the
tube were loaded on a 10% polyacrylamide gel and subjected to
electrophoresis. The separated proteins were transferred to a poly-
vinylidene diﬂuoride membrane and analyzed by Western blotting.
MV puriﬁcation
Infected RK-13 cells were harvested and collected by low-speed
centrifugation. Cells were then resuspended and disrupted by Dounce
homogenization. Cell suspensions were clariﬁed by low-speed
centrifugation and MV puriﬁed by centrifugation through two 36%
sucrose cushions and one 25–40% sucrose gradient.
SDS-PAGE
Cells were lysed in 0.2% NP-40, 10 mM Tris, pH 7.4, 10 mM CaCl2,
10 mM NaCl containing 8 μg/ml micrococcal nuclease (Worthington
Biochemical Corp., Lakewood, NJ) at 4 °C for 20 min. After addition of
lithium dodecyl sulfate sample buffer and reducing agent (Invitrogen,
Carlsbad, CA), cell lysateswere heated to 70 °C for 10min. Equal volumes
of lysate were analyzed by SDS-PAGE on a 10% bis–Tris–MES [2-(N-
morpholino)ethanesulfonic acid]–SDS running buffer (Invitrogen).
Western blot analysis
Proteins separated by SDS-PAGE were electrophoretically trans-
ferred to polyvinylidene diﬂuoride membrane (Invitrogen). Mem-
branes were blocked in Tris-buffered saline with 5% nonfat dry milk
and 0.05% Tween 20 and then incubated with antibodies for 1 h at
room temperature or overnight at 4 °C. Protein bands were visualized
by chemiluminescence using West-Pico or Dura kits (Pierce Biotech-
nology, Inc., Rockford, IL).
Confocal microscopy
HeLa cells, grown on glass coverslips in 12-well plates, were
infected at multiplicity of 0.5 PFU per cell. At 24 h post-infection, cellswere ﬁxed with 4% paraformaldehyde in phosphate-buffered saline
(PBS) for 7 min at room temperature, washed three times with PBS,
and then permeabilized for 10 min with 0.1% Triton X-100 in PBS at
room temperature. Cells were blocked for 1 h with 10% fetal bovine
serum in PBS, followed by incubation with primary antibody at room
temperature. Cells were washed three times in PBS, followed by
incubation with Alexa Fluor-conjugated secondary antibody (Invitro-
gen) at room temperature. After cells were washed three times with
PBS, DNA was stained with DAPI, and coverslips were mounted on
slides with Mowiol. Images were collected with a Leica TCS-NT/SP2
inverted confocal microscope system.
Cell surface biotinylation
HeLa cells were infected with vA43V5. At 18 h post-infection, cells
were washed twice with PBS containing Mg2+ and Ca2+and then
incubated with 0.5 mg/ml of the membrane-impermeable EZ-Link
Sulfo-NHS-LC-Biotin (sulfosuccinimidyl-6-[biotinamido] hexanoate)
(Pierce) dissolved in PBS on ice for 20 min. Cells were washed with
PBS and quenched with 10% fetal bovine serum for 20 min on ice and
then washed twice again. Cells were then lysed with NP-40 detergent
and the biotinylated proteins were afﬁnity puriﬁed on a NeutrAvidin
gel (Pierce).
IN infection model
Female BALB/c mice were purchased from Taconic (Germantown,
NY) and maintained in a pathogen-free environment in sterile
microisolator cages. Groups of 7-week-old mice were anesthetized
by inhalation of isoﬂurane and inoculated via the IN route with a 20-μl
suspension of puriﬁed VACV into one nostril. Mice wereweighed daily
for 2 weeks following challenge and were euthanized when they lost
30% of their initial body weight, according to a protocol approved by
the National Institute of Allergy and Infectious Diseases Animal Care
and Use Committee. The inocula were titered in order to conﬁrm the
dose administered.
Ear pinna infection model
Female BALB/c mice were anaesthetized with avertin and
inoculated intradermally with 104 PFU of VACV in a 10-μl suspension.
Lesions were measured daily with a micrometer. Ears were removed
and placed in 2 ml of PBS with 0.05% bovine serum albumin and kept
at −80 °C until use. Ears were thawed, cut into 1 mm pieces and
treated with collagenase for 3–4 h at 37 °C, frozen and thawed three
times, and sonicated three times for 30 s. Viral titers were determined
by plaque assay on BS-C-1 cells.
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